Showing 1-7 of 7

Sorted By:

  • Breast Cancer: Alliance A011401

    This study is being done to see if losing weight may help prevent breast cancer from coming back (recurring).

  • Breast Cancer: Alliance A011502 (ABC Study)

    The purpose of this study is to compare any good and bad effects of using aspirin after someone has completed the usual chemotherapy, surgery and/or radiation therapy for breast cancer.

  • Breast Cancer: EA1131

    The purpose of this study is to compare getting more treatment with capecitabine (i.e. one of the usual approaches), to any good and bad effects of getting more treatment with a platinum-based chemotherapy (cisplatin or carboplatin), after surgery for patients with triple-negative breast cancer.

  • Breast Cancer: NRG-BR003

    The purpose of this study is to compare the good and bad effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin.

  • Breast Cancer: S1418/BR006

    The purpose of this study is to compare the usual approach (i.e. no more treatment or additional post-operative chemotherapy), to any effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) after surgery.

  • Lung Cancer (Non-small cell): EA5142

    The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO®), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer.

  • Psychological Changes in Cancer Patients

    Researchers at The Ohio State University previously put together and tested From Cancer to HealthTM, a biobehavioral treatment designed specifically for cancer patients. Mental health professionals at Gilda’s Club Quad Cities have been trained to deliver the treatment to additional patients. This study will determine how effective the treatment is in reducing distress with new patients at Gilda’s Club Quad Cities.

View Additional Section Content

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email